Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Low-risk gestational trophoblastic neoplasia (FIGO score 0 to 6), drawn from the whole corpus: 1 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Methotrexate and actinomycin D have never been compared head to head with the regimens most centres use.
Which resistant patients should receive immunotherapy rather than EMA-CO is not settled.
Overtreatment of quiescent disease with persistently low hCG is a risk.
Care is centralised in only a few countries.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 8 changes by month →When this page itself was last checked or edited.
hCG normalisation in 8 of 15 women (53 percent) with single-agent chemotherapy-resistant disease, none of whom relapsed; grade 1 to 2 adverse events in 93 percent and no treatment-related grade 3 events.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.